Welcome to our dedicated page for MaxCyte news (Ticker: MXCT), a resource for investors and traders seeking the latest updates and insights on MaxCyte stock.
MaxCyte, Inc. (NASDAQ: MXCT) is a pioneering commercial cell-engineering company dedicated to advancing cell-based research and next-generation cell therapeutic discovery, development, and commercialization. At the heart of MaxCyte’s offerings is their proprietary Flow Electroporation® platform, which seamlessly facilitates the intricate engineering of a diverse range of cells, making it indispensable for modern cell therapy advancements.
MaxCyte’s core business model revolves around the sale and licensing of their cutting-edge instruments and single-use disposable processing assemblies. The company’s ExPERT™ platform, a next-generation suite of electroporation technology, delivers unparalleled transfection efficiency, scalability, and functionality. This platform is pivotal in supporting the growing cell therapy market, catering to needs from the discovery phase through to full-scale commercialization.
Recent achievements highlight MaxCyte’s significant role in the industry. For instance, Imugene is leveraging MaxCyte’s technology to support its azer-cel CAR T product candidate, potentially a ground-breaking treatment for blood cancer. Meanwhile, Wugen and Be Biopharma also utilize MaxCyte’s platforms to drive forward their innovative cancer therapies and engineered B cell medicines, respectively. These collaborations not only underscore the efficacy and versatility of MaxCyte’s technology but also expand its footprint across various therapeutic areas.
Financially, MaxCyte benefits from a robust revenue model that includes platform licensing fees, annual license fees, and program-related revenue. Their diverse portfolio of partners and extensive clinical and commercial collaborations highlight the trust and reliance placed on MaxCyte's technologies within the biotech industry.
As a company, MaxCyte is unwavering in its commitment to cell engineering excellence. With over two decades of experience, the company has honed its expertise in building best-in-class platforms, perfecting transfection workflows, and pushing the boundaries of current processes to innovate future solutions. Their extensive intellectual property portfolio and comprehensive support services for partners underscore their aim to transform human health through cutting-edge cell engineering.
MaxCyte continues to be at the forefront of cell engineering innovations, partnering with leading biotech firms globally and providing the tools necessary to accelerate the development of life-saving therapies. For more information, visit maxcyte.com and follow MaxCyte on social media platforms like X (formerly Twitter) and LinkedIn.
MaxCyte (Nasdaq: MXCT; LSE: MXCT), a cell-engineering platform technology company, has announced its participation in two upcoming investor conferences. The company will engage in fireside chats at the Stifel 2024 Healthcare Conference on November 18th at 10:55 AM ET and the Stephens Annual Investment Conference on November 19th at 3:00 PM CT. Interested parties can access live and archived webcasts of both events through MaxCyte's investor relations website.
MaxCyte, Inc. (Nasdaq: MXCT; LSE: MXCT) has appointed Cynthia Collins to its Board of Directors as a non-executive director, effective October 14, 2024. Collins will serve on the board's compensation committee, increasing the total Board of Directors to 10 members. With over 40 years of experience in biotechnology and cell and gene medicines, Collins brings valuable expertise to MaxCyte. Her most recent role was as CEO of Editas Medicine, where she was involved in dosing the first patient with an in-vivo gene modified therapy. Collins has also held CEO positions at Human Longevity Inc., GE Healthcare's Cell Therapy and Lab Businesses, and GenVec, Inc. She currently serves on the boards of several healthcare companies and holds a BS in Microbiology from the University of Illinois and an MBA from The University of Chicago Booth School of Business.
MaxCyte, Inc. (NASDAQ: MXCT; LSE: MXCT), a leading cell-engineering focused company, has announced it will release its third quarter 2024 financial results after the U.S. market close on Wednesday, November 6th, 2024. The company, which provides enabling platform technologies for cell therapeutics and bioprocessing applications, will host a conference call to discuss the financial results at 4:30 p.m. Eastern Time on the same day.
Investors interested in participating in the earnings conference call are required to register online, with registration recommended at least a day in advance. A live and archived webcast of the event will be available on the 'Events' section of MaxCyte's investor relations website at https://investors.maxcyte.com/.
MaxCyte, Inc. (Nasdaq: MXCT; LSE: MXCT) has appointed Ali Soleymannezhad as Chief Commercial Officer, effective September 11, 2024. In his new role, Soleymannezhad will lead MaxCyte's commercial operations to increase adoption of the ExPERT Platform and expand the company's market impact in Cell and Gene Therapy. Previously, he served as Executive Vice President of Bioprocessing at MaxCyte, leading global product development and marketing strategy for the bioprocessing business.
Soleymannezhad brings 20 years of technical sales, marketing, and product development experience to his new role. Prior to joining MaxCyte, he held executive positions at Tosoh Bioscience, including Executive Vice President for the Separations and Purification business, overseeing a team of 140 employees across four global sites. MaxCyte's CEO, Maher Masoud, expressed confidence in Soleymannezhad's ability to drive future growth for the company.
MaxCyte (Nasdaq: MXCT; LSE: MXCT) and Kamau Therapeutics have entered a strategic platform license agreement. Kamau gains non-exclusive rights to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform for research, clinical, and commercial purposes. In return, MaxCyte will receive annual licensing fees and program-related revenue.
Kamau, a clinical-stage company, is developing gene correction therapies using homology-directed repair (HDR) editing. Their lead program, nula-cel, targets sickle cell disease (SCD). This partnership aims to optimize Kamau's clinical manufacturing process and expedite the development of potential cures for genetic diseases.
MaxCyte's ExPERT™ platform offers high transfection efficiency, scalability, and enhanced functionality for complex cell engineering. This marks MaxCyte's 29th clinical/commercial partnership, contributing to its pre-commercial milestone revenue stream.
MaxCyte Inc. (NASDAQ: MXCT; LSE: MXCT), a leader in cell-engineering and platform technologies for cell-based therapeutics and bioprocessing applications, has announced its participation in the Virtual Craig-Hallum Capital Group Bioprocessing Conference. The event is scheduled for Thursday, September 19th at 9:30 am ET.
Company management will be presenting at the conference, providing insights into MaxCyte's innovative technologies and market position. For those unable to attend live, a replay of the event will be made available on the 'Events' section of MaxCyte's investor relations website at https://investors.maxcyte.com/.
This participation underscores MaxCyte's commitment to engaging with the investment community and showcasing its advancements in cell engineering and bioprocessing technologies.
MaxCyte (NASDAQ: MXCT) reported Q2 2024 financial results and updated full-year guidance. Total revenue reached $10.4 million, up 15% year-over-year. Core business revenue declined 9% to $7.6 million, while SPL Program-related revenue surged 279% to $2.9 million. The company signed five new SPL clients year-to-date, bringing the total to 28. MaxCyte affirmed its 2024 core business revenue guidance of flat to 5% growth and increased SPL Program-related revenue guidance to approximately $6 million. The company expects to end 2024 with at least $180 million in total cash, cash equivalents, and investments.
MaxCyte (NASDAQ: MXCT; LSE: MXCT), a leader in cell-engineering platform technologies, will announce its Q2 2024 financial results on August 6, 2024, after the U.S. market closes. The company invites investors to join a conference call at 4:30 p.m. Eastern Time, where management will discuss these results. Interested participants should register online in advance. A live and archived webcast of the call will be available on the MaxCyte website.
MaxCyte, a leader in cell-engineering technologies, announced its participation in the William Blair 44th Annual Growth Stock Conference. The event is scheduled for June 5th at 2:40 pm CT. The session will be available live and archived on MaxCyte's investor relations website. MaxCyte focuses on advancing cell-based therapeutics and bioprocessing applications, emphasizing discovery, development, and commercialization.
MaxCyte has signed a strategic platform license agreement with Legend Biotech to accelerate the discovery and development of cell therapies. Under this non-exclusive worldwide license, Legend Biotech will use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform for various cell types, including T cells and NK cells. MaxCyte will receive annual licensing fees, clinical development milestones, and royalties on net sales of the licensed products. This marks MaxCyte’s 28th clinical/commercial partnership, emphasizing its role in advancing cell-based therapeutics.
The partnership aims to enhance Legend Biotech’s non-viral engineered therapeutic pipeline, leveraging MaxCyte’s expertise in scalable cell engineering and regulatory support. The ExPERT™ platform provides high transfection efficiency and seamless scalability, essential for developing innovative cell therapies. Both companies aim to transform the treatment landscape and meet expanding clinical and commercial needs.
FAQ
What is the current stock price of MaxCyte (MXCT)?
What is the market cap of MaxCyte (MXCT)?
What does MaxCyte, Inc. specialize in?
What is the ExPERT™ platform?
How does MaxCyte generate revenue?
What recent partnerships has MaxCyte formed?
What are some key features of MaxCyte’s Flow Electroporation® technology?
Where can I find more information about MaxCyte’s financial performance?
What is the significance of MaxCyte’s partnership with Imugene?
How long has MaxCyte been in the cell engineering industry?
What products are included in the ExPERT™ family?
How does MaxCyte support its partners?
